CSA: Thực hành nông nghiệp thông minh với khí hậu ở Việt Nam

During the last five years, Vietnam has been one of the countries most affected by climate change. Severe typhoons, flooding, cold spells, salinity intrusion, and drought have affected agriculture production across the country, from upland to lowland regions. Fortunately for Vietnam, continuous work in developing climate-smart agriculture has been occurring in research organizations and among innovative farmers and entrepreneurs. Application of various CSA practices and technologies to adapt to the impact of climate change in agriculture production have been expanding. However, there is a need to accelerate the scaling process of these practices and technologies in order to ensure growth of agriculture production and food security, increase income of farmers, make farming climate resilient, and contribute to global climate change mitigation. This book aims to provide basic information to researchers, managers, and technicians and extentionists at different levels on what CSA practices and technologies can be up scaled in different locations in Vietnam

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Background Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population. Methods AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Findings Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months. Interpretation Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke

Hydrothermally synthesized nanostructured LiMnxFe1−xPO4 (x = 0–0.3) cathode materials with enhanced properties for lithium-ion batteries

Abstract Nanostructured cathode materials based on Mn-doped olivine LiMnxFe1−xPO4 (x = 0, 0.1, 0.2, and 0.3) were successfully synthesized via a hydrothermal route. The field-emission scanning electron microscopy (SEM) and energy-dispersive X-ray spectroscopy (EDS) analyzed results indicated that the synthesized LiMnxFe1−xPO4 (x = 0, 0.1, 0.2, and 0.3) samples possessed a sphere-like nanostructure and a relatively homogeneous size distribution in the range of 100–200 nm. Electrochemical experiments and analysis showed that the Mn doping increased the redox potential and boosted the capacity. While the undoped olivine (LiFePO4) had a capacity of 169 mAh g−1 with a slight reduction (10%) in the initial capacity after 50 cycles (150 mAh g−1), the Mn-doped olivine samples (LiMnxFe1−xPO4) demonstrated reliable cycling tests with negligible capacity loss, reaching 151, 147, and 157 mAh g−1 for x = 0.1, 0.2, and 0.3, respectively. The results from electrochemical impedance spectroscopy (EIS) accompanied by the galvanostatic intermittent titration technique (GITT) have resulted that the Mn substitution for Fe promoted the charge transfer process and hence the rapid Li transport. These findings indicate that the LiMnxFe1−xPO4 nanostructures are promising cathode materials for lithium ion battery applications

Influence of the Preparation Method on Some Characteristics of Alginate/Chitosan/Lovastatin Composites

This study investigates the effects of direct and indirect dispersion methods for lovastatin solid dispersion (LSD) in alginate (AG)/chitosan (CS) composites on the characteristics and properties of the AG/CS/LSD composites. The preparation method significantly influences the structure, morphology, and LSD size distribution of the composites as well as the drug release of LSD from the samples. The differences in dispersion methods for LSD lead to differences in the interaction between the components, the structure, and the control drug release of LSD. Lovastatin was released from the samples containing LSD in two stages (a fast release stage and a slow release stage), and the drug release content prepared using the indirect method is lower than that prepared using the direct method in the same buffer solution. After 32 h of testing, the released LSD content from the indirect and direct LSD dispersion methods in pH 2 and pH 7.4 buffer solutions was 87–94% and 41–61%, respectively. Drug release kinetics from the above samples in solutions with different pH values was also set up

Investigation of Chitosan Nanoparticles Loaded with Protocatechuic Acid (PCA) for the Resistance of <i>Pyricularia oryzae</i> Fungus against Rice Blast

In this study, chitosan nanoparticles were used as a carrier for Protocatechuic acid (PCA) to resist Pyricularia oryzae against rice blast. The final compound was characterized using zeta potentials for its surface electricity, Fourier transform infrared (FT-IR) analysis and transmission electron microscopy (TEM) were conducted for functional groups and for particle sizes and shape, respectively. The zeta potential results showed that loading PCA causes chitosan nanoparticle (CSNP) to decrease in surface electrons. The TEM images revealed that the particle size of chitosan (CS), although increasing in size when carrying PCA molecules, showed sufficient size for reasonable penetration into fungal cells. The FT-IR analysis showed that all functional group in CSNP carried PCA matched with previous studies. The antifungal test showed that diameters of inhibition zone of CS increases significantly after loading PCA, exhibiting the strongest antimicrobial effect on the Pyricularia oryzae fungus compared with weaker effects exhibited by CSNP alone or PCA. Our results suggested that CSNP loaded with PCA could be a potential compound for eradication of Pyricularia oryzae and that further testing on in vitro rice plants is recommended to reaffirm this possibility

Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration

Background and Purpose: The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures. After trial medication was ceased at 6 months, survivors were followed to 12 months post-randomization. This preplanned secondary analysis aimed to determine any sustained or delayed effects of fluoxetine at 12 months post-randomization. Methods: AFFINITY was a randomized, parallel-group, double-blind, placebo-controlled trial in adults (n=1280) with a clinical diagnosis of stroke in the previous 2 to 15 days and persisting neurological deficit who were recruited at 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10) between 2013 and 2019. Participants were randomized to oral fluoxetine 20 mg once daily (n=642) or matching placebo (n=638) for 6 months and followed until 12 months after randomization. The primary outcome was function, measured by the modified Rankin Scale, at 6 months. Secondary outcomes for these analyses included measures of the modified Rankin Scale, mood, cognition, overall health status, fatigue, health-related quality of life, and safety at 12 months. Results: Adherence to trial medication was for a mean 167 (SD 48) days and similar between randomized groups. At 12 months, the distribution of modified Rankin Scale categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio, 0.93 [95% CI, 0.76–1.14]; P =0.46). Compared with placebo, patients allocated fluoxetine had fewer recurrent ischemic strokes (14 [2.18%] versus 29 [4.55%]; P =0.02), and no longer had significantly more falls (27 [4.21%] versus 15 [2.35%]; P =0.08), bone fractures (23 [3.58%] versus 11 [1.72%]; P =0.05), or seizures (11 [1.71%] versus 8 [1.25%]; P =0.64) at 12 months. Conclusions: Fluoxetine 20 mg daily for 6 months after acute stroke had no delayed or sustained effect on functional outcome, falls, bone fractures, or seizures at 12 months poststroke. The lower rate of recurrent ischemic stroke in the fluoxetine group is most likely a chance finding. REGISTRATION: URL: http://www.anzctr.org.au/ ; Unique identifier: ACTRN12611000774921